Related Experiment Video
Updated: Jun 15, 2026

08:01
Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
Nicotinic acetylcholine receptor interaction with beta-amyloid: molecular, cellular, and physiological consequences
1Department of Neurology, University of Texas Medical Branch, Galveston, TX 77555-0616, USA.
Current Alzheimer Research
|March 9, 2010
Summary
Alzheimer's disease involves amyloid-beta (Abeta) and nicotinic acetylcholine receptors (nAChRs). This review explores how Abeta impacts nAChRs at multiple levels, contributing to both normal function and disease.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- Alzheimer's disease (AD) is linked to elevated amyloid-beta peptide (Abeta) and reduced nicotinic acetylcholine receptors (nAChRs).
- The interaction between Abeta and nAChRs is a key area of research in understanding AD.
- Previous studies have focused on characterizing the effects of varying Abeta concentrations on nAChRs.
Purpose of the Study:
- To review current knowledge on the Abeta-nAChR interaction.
- To elucidate the molecular, cellular, and physiological consequences of this interaction.
- To understand the role of Abeta-nAChR interaction in normal physiology and Alzheimer's disease pathogenesis.
Main Methods:
- Literature review of existing research on Abeta-nAChR interactions.
- Analysis of studies at molecular, cellular, and physiological levels.
- Synthesis of findings to connect Abeta-nAChR interaction to AD etiology.
Main Results:
- Abeta peptides interact with nAChRs, influencing their function.
- Different concentrations of Abeta have distinct effects on nAChRs.
- These interactions are observed across molecular, cellular, and physiological systems.
Conclusions:
- The Abeta-nAChR interaction is a significant factor in Alzheimer's disease.
- Understanding this interaction is crucial for developing therapeutic strategies for AD.
- Further research is needed to fully elucidate the mechanisms involved.
Related Concept Videos
Cholinergic Receptors: Nicotinic
Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...

